Pingchen Fan

This inventor holds 63 USPTO granted patents and 22 published patent applications, plus 12 CIPO patents and 22 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D). Top assignees: Chemocentryx, Inc., Amgen Inc., Tularik Limited. Active years: 2004-2026.

USPTO Granted Patents = 63 (Patent Applications = 22)

% Patents Active = 85.7

CIPO Patents = 12 (Patent Applications = 14)

EPO Patents = 22 (Patent Applications = 29)

Average Co-Inventor Count = 8.4

ph-index = 10

Forward Citations = 351(Granted Patents)

Forward Citations (Not Self Cited) = 169(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Newark, CA (US) (2004 - 2006)
San Mateo, CA (US) (2010)
Hayward, CA (US) (2023)
Fremont, CA (US) (2004 - 2024)

Company Filing History:

4. 1 out of 834,411

Other

patents

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

PD-L1 Treatments

C5aR Inhibitors

Oxindole Derivatives

Aza-Aryl Compounds

Heteroaryl-Biphenyl Amides

Deuterated Compounds

Diaryl Substituted Compounds

Fused Ring Compounds

Immunomodulators

Prodrugs

Processes and Intermediates

Diazole Lactams

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12611404 - Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides (2026-04-28),

2. 12533354 - Triaryl compounds for treatment of PD-L1 diseases (2026-01-27),

3. 12497383 - Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases (2025-12-16),

4. 12448373 - Azetidinyl-acetamides as CXCR7 inhibitors (2025-10-21),

5. 12371433 - Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases (2025-07-29),

6. 12268675 - Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors (2025-04-08),

7. 12139475 - 2-oxindole compounds (2024-11-12),

8. 11866429 - Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases (2024-01-09),

9. 11845729 - Processes and intermediates in the preparation of C5aR antagonists (2023-12-19),

10. 11807609 - Deuterated compounds as immunomodulators (2023-11-07),

11. 11773091 - 6-5 fused rings as C5a inhibitors (2023-10-03),

12. 11759454 - Diazole lactams (2023-09-19),

13. 11713307 - Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases (2023-08-01),

14. 11608336 - Prodrugs of fused-bicyclic C5aR antagonists (2023-03-21),

15. 11485737 - Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors (2022-11-01),

Title: The Innovative Contributions of Pingchen Fan

Introduction: Pingchen Fan, located in Fremont, CA, has made significant strides in the field of pharmaceutical innovations. With an impressive portfolio of 57 patents, his work focuses on developing novel compounds that provide therapeutic solutions for various health conditions.

Latest Patents: Among Pingchen Fan's latest patents are two notable contributions. The first patent involves 2-oxindole compounds, which are oxindole compounds aimed at the treatment of CCR(9) mediated conditions or diseases. The second patent centers on heteroaryl-biphenyl amines, which serve as immunomodulators for the treatment of PD-L1 diseases. These compounds include a specific Formula (I) that encompasses stereoisomers and pharmaceutically acceptable salts, with detailed descriptions of the components involved in their composition and usage. In addition, methods related to the preparation and application of these compounds, as well as the pharmaceutical compositions that feature them, are also disclosed.

Career Highlights: Pingchen Fan's career includes significant tenures at leading biotechnology companies, notably Chemocentryx, Inc. and Amgen Inc. His role in these organizations has been pivotal in pioneering drug development and advancing medical therapies.

Collaborations: Throughout his career, Pingchen has collaborated with several talented professionals, including Penglie Zhang and Yibin Zeng. These partnerships have fueled further innovation and facilitated the development of impactful pharmaceutical solutions.

Conclusion: Pingchen Fan exemplifies the spirit of innovation within the pharmaceutical industry. His extensive patent portfolio and ongoing research highlight his commitment to advancing health solutions through science and collaboration. As the field of medicine continues to evolve, contributions from inventors like Fan play an essential role in driving progress and improving patient outcomes.